-

DENTSPLY INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate Claims On Behalf of Investors of Dentsply Sirona, Inc. - XRAY

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), continues to investigate claims on behalf of investors of Dentsply Sirona, Inc. (NasdaqGS: XRAY). Such investors are advised to contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit us at https://www.ksfcounsel.com/cases/nasdaqgs-xray/ to learn more.

On April 19, 2022, the Company disclosed that it “terminated” CEO Donald Casey “effective immediately,” and further revealed disappointing financial news including expected net sales of around $965 million, down 1.4% year over year and lower than the $1.02 billion expected by analysts and adjusted earnings per share of between $0.48 and $0.52, well below the consensus earnings estimate of $0.67. Then, on May 10, 2022, the Company disclosed an ongoing investigation by the Audit and Finance Committee of the Board of Directors, outside counsel and a forensic accounting firm into whether “former and current members of senior management” used improper means to achieve executive compensation goals and other matters relating to financial reporting.

The investigation concerns whether Dentsply and certain of its officers and/or directors have engaged in fraud, negligence or other unlawful business practices.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Industry:

Kahn Swick & Foti, LLC

NASDAQ:XRAY
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

CoreWeave 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against CoreWeave, Inc. - CRWV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against CoreWeave, Inc. (NasdaqGS: CRWV), if they purchased or otherwise acquired the Company’s securities between March 28, 2025 and December 15, 2025, inclusive (the “Class Period”). This action is pending in the U...

Talkspace Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Talkspace, Inc. - TALK

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Talkspace, Inc. (NasdaqCM: TALK) to Universal Health Services, Inc. (NYSE: UHS). Under the terms of the proposed transaction, shareholders of Talkspace will receive $5.25 in cash for each share of Talkspace that they own. KSF is seeking to determine whether this consideration and the process that le...

Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Soleno Therapeutics who were adversely affected by alleged securities fraud between March 26, 2025 and November 4, 2025. Follow th...
Back to Newsroom